Last updated on November 2017

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Product in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)


Brief description of study

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Product in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

Detailed Study Description

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Product in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

Patient Inclusion Criteria:

  • Provision of written informed consent prior to any study-specific procedures.
  • Self-reported active symptoms of OIC at screening (<3 SBMs/week and experiencing =1 reported symptom of hard/lumpy stools, straining, or sensation of incomplete evacuation/anorectal obstruction in at least 25% of BMs over the previous 4 weeks); and Documented confirmed OIC (<3 SBMs/week on average over the 2-week OIC confirmation period.
  • Receiving a stable maintenance opioid regimen consisting of a total daily dose of 30 mg to 1000 mg of oral morphine, or equianalgesic amount(s) of 1 or more other opioid therapies for a minimum of 4 weeks prior to screening for non-cancer-related pain with no anticipated change in opioid dose requirement over the proposed study period as a result of disease progression.
  • Willingness to stop all laxatives and other bowel regimens including prune juice and herbal products throughout the 2-week OIC confirmation period and the 12-week treatment period, and to use only bisacodyl as rescue medication if a BM has not occurred within at least 72 hours of the last recorded BM.

Patient Exclusion Criteria:

  • Patients receiving Opioid regimen for treatment of pain related to cancer.
  • History of cancer within 5 years from first study visit with the exception of basal cell cancer and squamous cell skin cancer.
  • Medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation.
  • Other issues to the gastrointestinal tract that could impose a risk to the patient.
  • Pregnancy or lactation.

Clinical Study Identifier: TX1352

Contact Investigators or Research Sites near you

Start Over

Suzi DeFiesta

CSI Research Inc
Alpharetta, GA USA

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.